2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 12

Non-Criteria Antiphospholipid Antibodies in Obstetrical “seronegative Anti-Phospholipid syndrome”
Abstract Number: 582

Non-Steroidal Anti-Inflammatory Drugs in Axial Spondyloarthritis: A Cochrane Review
Abstract Number: 2778

Non-Systemic Vasculitic Neuropathy: Presentation, Therapeutic Management and Outcome
Abstract Number: 1420

Non-Use of Glucocorticoid and Osteoarthritis Absence As Predictors of Clinical Remission in AR
Abstract Number: 2635

Noncalcified Plaque Progression in Systemic Lupus Erythematosus
Abstract Number: 2105

Nonsurgical Treatment Patterns in Patients with Chronic Spinal Cord Injury
Abstract Number: 417

Normal Scores of “0” (floor effects) Are Seen in 33-83% of Patients with Rheumatoid Arthritis (RA) on 8 HAQ Activities Which Also Are Found on the MDHAQ, but in Fewer Than 32% of Patients on 2 Unique MDHAQ Complex Activities “Walk 2 Miles or 3 Kilometers,” and “Participate in Recreation and Sports.”
Abstract Number: 1573

Norwegian Psoriatic Arthritis Patients Are More Obese Than Rheumatoid Arthritis and Axial Spondyloarthropathy Patients
Abstract Number: 1855

Not Keeping up with the Times: High Mortality and Early Death Due to Disease in North American Natives with Systemic Lupus Erythematosus (SLE)
Abstract Number: 1149

Novel Adherence Measures for Infusible Therapeutic Agents in Rheumatoid Arthritis
Abstract Number: 987

Novel Auto-Antigen in Aortic Aneurysms of Large Vessel Vasculitis
Abstract Number: 2209

Novel Biomarkers of Extracellular Matrix Remodeling in Inflammatory Bowel Disease: Different Patterns of Gut Injury in UC and CD
Abstract Number: 1044

Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis
Abstract Number: 2877

Novel Function of Tocilizumab As a Modulator of Interleukin-27-Mediated Anti-Inflammatory Responses
Abstract Number: 784

Novel Inhibitory Effects of Mast Cells in Aortitis Involves Aortic Expression of Suppressor of Cytokine Signaling-1

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].